Vennegoor A - Search Results

1

Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody.

Rispens T, Leeuwen Av, Vennegoor A, Killestein J, Aalberse RC, Wolbink GJ, Aarden LA. Rispens T, et al. Among authors: vennegoor a. Anal Biochem. 2011 Apr 15;411(2):271-6. doi: 10.1016/j.ab.2011.01.001. Epub 2011 Jan 7. Anal Biochem. 2011. PMID: 21216215

2

T lymphocytes impair P-glycoprotein function during neuroinflammation.

Kooij G, van Horssen J, de Lange EC, Reijerkerk A, van der Pol SM, van Het Hof B, Drexhage J, Vennegoor A, Killestein J, Scheffer G, Oerlemans R, Scheper R, van der Valk P, Dijkstra CD, de Vries HE. Kooij G, et al. Among authors: vennegoor a. J Autoimmun. 2010 Jun;34(4):416-25. doi: 10.1016/j.jaut.2009.10.006. Epub 2009 Dec 2. J Autoimmun. 2010. PMID: 19959334

3

Natalizumab drug holiday in multiple sclerosis: poorly tolerated.

Killestein J, Vennegoor A, Strijbis EM, Seewann A, van Oosten BW, Uitdehaag BM, Polman CH. Killestein J, et al. Among authors: vennegoor a. Ann Neurol. 2010 Sep;68(3):392-5. doi: 10.1002/ana.22074. Ann Neurol. 2010. PMID: 20661928

4

Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS.

van der Voort LF, Vennegoor A, Visser A, Knol DL, Uitdehaag BM, Barkhof F, Oudejans CB, Polman CH, Killestein J. van der Voort LF, et al. Among authors: vennegoor a. Neurology. 2010 Oct 5;75(14):1228-33. doi: 10.1212/WNL.0b013e3181f6c556. Neurology. 2010. PMID: 20921509

5

Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS.

Vennegoor A, Wattjes MP, van Munster ET, Kriekaart RL, van Oosten BW, Barkhof F, Killestein J, Polman CH. Vennegoor A, et al. Neurology. 2011 Feb 8;76(6):574-6. doi: 10.1212/WNL.0b013e31820b7644. Neurology. 2011. PMID: 21300973 No abstract available.

6

Antibodies against aquaporin-4 in neuromyelitis optica: distinction between recurrent and monophasic patients.

Ketelslegers IA, Modderman PW, Vennegoor A, Killestein J, Hamann D, Hintzen RQ. Ketelslegers IA, et al. Among authors: vennegoor a. Mult Scler. 2011 Dec;17(12):1527-30. doi: 10.1177/1352458511412995. Epub 2011 Aug 9. Mult Scler. 2011. PMID: 21828202

7

Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped.

Rispens T, Vennegoor A, Wolbink GJ, Polman CH, Killestein J. Rispens T, et al. Among authors: vennegoor a. Mult Scler. 2012 Jun;18(6):899-901. doi: 10.1177/1352458511431073. Epub 2011 Dec 19. Mult Scler. 2012. PMID: 22183929

8

Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.

Vennegoor A, Rispens T, Strijbis EM, Seewann A, Uitdehaag BM, Balk LJ, Barkhof F, Polman CH, Wolbink G, Killestein J. Vennegoor A, et al. Mult Scler. 2013 Apr;19(5):593-600. doi: 10.1177/1352458512460604. Epub 2012 Sep 19. Mult Scler. 2013. PMID: 22992450

9

Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patients.

van Rossum JA, Vennegoor A, Balk L, Uitdehaag BM, Polman CH, Killestein J. van Rossum JA, et al. Among authors: vennegoor a. Mult Scler. 2014 Jan;20(1):108-11. doi: 10.1177/1352458513495582. Epub 2013 Jul 4. Mult Scler. 2014. PMID: 23828867

10

Drug interference in immunogenicity assays depends on valency.

Rispens T, Hart MH, Ooijevaar-de Heer P, van Leeuwen A, Vennegoor A, Killestein J, Wolbink GJ, van der Kleij D. Rispens T, et al. Among authors: vennegoor a. J Pharm Biomed Anal. 2013 Nov;85:179-85. doi: 10.1016/j.jpba.2013.07.022. Epub 2013 Jul 30. J Pharm Biomed Anal. 2013. PMID: 23954437

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

28 results

Search Page